Evidence map›Paper›PMID 39494523›Full record

ArticleCancer medicine2024

Patient-Initiated Nationwide Survey on Testing for Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer in Japan.

Satoshi Ikeda, Kazuo Hasegawa, Kenta Kachi, Akihiro Yanagisawa, Sachiko Kawakami, Shinsuke Hamasaki, Sachiko Watanabe, Aki Yoshikawa, Takayuki Takahama, Kazuhiko Nakagawa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Satoshi IkedaDepartment of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan.ORCID https://orcid.org/0000-0001-5203-7911
Kazuo HasegawaJapan Lung Cancer Alliance, Yokohama, Japan.
Kenta KachiGeneral Incorporated Association Alliance for Lung Cancer, Yokohama, Japan.
Akihiro YanagisawaGeneral Incorporated Association Alliance for Lung Cancer, Yokohama, Japan.
Sachiko KawakamiGeneral Incorporated Association Alliance for Lung Cancer, Yokohama, Japan.
Shinsuke HamasakiGeneral Incorporated Association Alliance for Lung Cancer, Yokohama, Japan.
Sachiko WatanabeGlobal Health Consulting Japan, Tokyo, Japan.
Aki YoshikawaGlobal Health Consulting Japan, Tokyo, Japan.
Takayuki TakahamaDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan.
Kazuhiko NakagawaDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Japan.ORCID https://orcid.org/0000-0003-1284-9776

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrevious reports indicated still low implementation rates of multigene testing for advanced non-small cell lung cancer (NSCLC) in Japan.

methodsThis is a retrospective study launched at the initiative of lung cancer patients. Patients with stage IV NSCLC from January 2019 to December 2022 were investigated for testing of 8 actionable oncogenic drivers with targeted therapies available as of 2022.

resultsA total of 15,719 patients were included. Between 2019 and 2022, the percentage of patients who were not tested for any actionable oncogenic drivers remained the same, ranging from 21.5% to 33.1%. However, since late 2021, the percentage of patients tested for five or more actionable oncogenic drivers has increased. Across hospital categories and regions, the number of actionable oncogenic drivers tested was similar.

conclusionsThis patient-initiated national survey in Japan reveals the recent nationwide increase in testing rates for actionable oncogenic drivers in Advanced NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdultAgedFemaleGenetic TestingHumansJapanMaleMiddle AgedOncogenesRetrospective StudiesSurveys and Questionnairesactionable oncogenic driversdiagnosis procedure combinationmultigene testingnon‐small cell lung cancertargeted therapy

Identifiers

PMID39494523
PMCPMC11532810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.